Doxycycline Medicine 04 June 2026 Extended indication Doxycycline in combination with standard of care for preventive treatment of post abdominal colorectal Surgical site infection in adults and elderly undergoing surgeries with incisions greater than 20 cm. Therapeutic value No estimate possible yet Total cost Registration phase Clinical trials Product Active substance Doxycycline Domain Infectious diseases Reason of inclusion New medicine (specialité) Main indication Bacterial infections Extended indication Doxycycline in combination with standard of care for preventive treatment of post abdominal colorectal Surgical site infection in adults and elderly undergoing surgeries with incisions greater than 20 cm. Current proprietary name Already available biosimilars / generics Proprietary name Manufacturer Advanz Portfolio holder Mechanism of action Antibiotic Route of administration Local Therapeutical formulation Powder for topical use Budgetting framework Intermural (MSZ) Centre of expertise Additional remarks Registration Registration route Centralised (EMA) Type of trajectory Normal trajectory Particularity New therapeutical formulation ATMP Submission date June 2026 Expected Registration July 2027 Orphan drug Registration phase Clinical trials Reimbursement Medicine sluice Additional remarks Therapeutic value Current treatment options Therapeutic value No estimate possible yet This assessment does not indicate any potential inclusion in the package. Substantiation De resultaten van de SHIELD II trial moeten worden afgewacht totdat er een inschatting gemaakt kan worden van de therapeutische waarde. Duration of treatment Frequency of administration Dosage per administration References NCT04411199 (SHIELD II) Additional remarks Expected patient volume per year Patient volume Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Expertopinie Additional remarks Het volume dat in aanmerking zal komen voor dit middel is afhankelijk van het aantal colorectale operatie met een incisie groter dan 20 cm. Expected cost per patient per year Cost € < 100.00 This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year. References medicijnkosten.nl; IHSI Additional remarks Betreft een nieuwe toedieningsvorm. De kosten per 100mg tablet zijn €0,58. Verwachte jaarlijkse kosten op basis van IHSI-inschatting, afgeleid van de mediane kosten voor dit geneesmiddel in Nederland. Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Indications off label use References Additional remarks Indication extension Indication extensions Indication extensions References Additional remarks Other information Additional remarks